EGFR and cancer: In this study, we used a 64Cu-labeled anti-epidermal growth factor receptor (EGFR) antibody cetuximab to obtain proof of concept for the integrated 64Cu therapy, since cetuximab has a high binding affinity for EGFR (which is overexpressed in a wide variety of cancers) and is commonly used to treat these cancers in clinical practice [26].